期刊
PHARMACEUTICALS
卷 14, 期 1, 页码 -出版社
MDPI
DOI: 10.3390/ph14010057
关键词
loss of heterozygosity; cancer therapy; drug development and cancer evolution
资金
- Swedish Cancer Foundation
- Swedish Research Council
- Swedish Foundation for Strategic Research
- Erling-Persson Family Foundation
- Swedish Children's Cancer Foundation
Loss of heterozygosity (LOH) is a common genetic event in cancer development, creating genetic differences between tumor and normal cells that provide opportunities for novel cancer therapies.
Loss of heterozygosity (LOH) is a common genetic event in the development of cancer. In certain tumor types, LOH can affect more than 20% of the genome, entailing loss of allelic variation in thousands of genes. This reduction of heterozygosity creates genetic differences between tumor and normal cells, providing opportunities for development of novel cancer therapies. Here, we review and summarize (1) mutations associated with LOH on chromosomes which have been shown to be promising biomarkers of cancer risk or the prediction of clinical outcomes in certain types of tumors; (2) loci undergoing LOH that can be targeted for development of novel anticancer drugs as well as (3) LOH in tumors provides up-and-coming possibilities to understand the underlying mechanisms of cancer evolution and to discover novel cancer vulnerabilities which are worth a further investigation in the near future.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据